title: Metabolomics data normalization with EigenMS.
abstract: Liquid chromatography mass spectrometry has become one of the analytical platforms of choice for metabolomics studies. However, LC-MS metabolomics data can suffer from the effects of various systematic biases. These include batch effects, day-to-day variations in instrument performance, signal intensity loss due to time-dependent effects of the LC column performance, accumulation of contaminants in the MS ion source and MS sensitivity among others. In this study we aimed to test a singular value decomposition-based method, called EigenMS, for normalization of metabolomics data. We analyzed a clinical human dataset where LC-MS serum metabolomics data and physiological measurements were collected from thirty nine healthy subjects and forty with type 2 diabetes and applied EigenMS to detect and correct for any systematic bias. EigenMS works in several stages. First, EigenMS preserves the treatment group differences in the metabolomics data by estimating treatment effects with an ANOVA model (multiple fixed effects can be estimated). Singular value decomposition of the residuals matrix is then used to determine bias trends in the data. The number of bias trends is then estimated via a permutation test and the effects of the bias trends are eliminated. EigenMS removed bias of unknown complexity from the LC-MS metabolomics data, allowing for increased sensitivity in differential analysis. Moreover, normalized samples better correlated with both other normalized samples and corresponding physiological data, such as blood glucose level, glycated haemoglobin, exercise central augmentation pressure normalized to heart rate of 75, and total cholesterol. We were able to report 2578 discriminatory metabolite peaks in the normalized data (p<0.05) as compared to only 1840 metabolite signals in the raw data. Our results support the use of singular value decomposition-based normalization for metabolomics data.
authors.affiliation: School of Mathematics and Physics, University of Tasmania, Hobart, TAS, Australia.
authors.forename: Yuliya V
authors.initials: YV
authors.lastname: Karpievitch
authors.affiliation: Menzies Research Institute Tasmania, University of Tasmania, Hobart, TAS, Australia.
authors.forename: Sonja B
authors.initials: SB
authors.lastname: Nikolic
authors.affiliation: Central Science Laboratory, University of Tasmania, Hobart, TAS, Australia.
authors.forename: Richard
authors.initials: R
authors.lastname: Wilson
authors.affiliation: Central Science Laboratory, University of Tasmania, Hobart, TAS, Australia.
authors.forename: James E
authors.initials: JE
authors.lastname: Sharman
authors.affiliation: Centre of Human & Aerospace Physiological Sciences, King's College London, London, United Kingdom; Fibrosis Discovery Performance Unit, GlaxoSmithKline R&D, Stevenage, United Kingdom.
authors.forename: Lindsay M
authors.initials: LM
authors.lastname: Edwards
mesh_terms: D000368:Aged; D002853:Chromatography, Liquid / Q000379:methods; D016208:Databases, Factual; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000378:metabolism*; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods; D055432:Metabolomics / Q000379:methods*; D008875:Middle Aged; D015203:Reproducibility of Results; D012984:Software